Therapeutic options of Angiotensin Receptor Neprilysin inhibitors (ARNis) in chronic heart failure with reduced ejection fraction: Beyond RAAS and sympathetic nervous system inhibition-Reference-Cited by-同舟云学术

Therapeutic options of Angiotensin Receptor Neprilysin inhibitors (ARNis) in chronic heart failure with reduced ejection fraction: Beyond RAAS and sympathetic nervous system inhibition

Published:2017-01 Issue: Volume:226 Page:132-135
ISSN:0167-5273
Container-title:International Journal of Cardiology
language:en
Short-container-title:International Journal of Cardiology

Author:

Volterrani Maurizio,Iellamo Ferdinando,Senni Michele,Piepoli Massimo F.

Publisher

Elsevier BV

Subject

Cardiology and Cardiovascular Medicine

Reference34 articles.

1. Relation of the renin–angiotensin–aldosterone system to clinical state in congestive heart failure;Dzau;Circulation,1981

2. Drug insight: aldosterone-receptor antagonists in heart failure — the journey continues;Kalidindi;Nat. Clin. Pract. Cardiovasc. Med.,2007

3. Aldosterone production is activated in failing ventricle in humans;Mizuno;Circulation,2001

4. Pathological hypertrophy and cardiac interstitium. Fibrosis and renin–angiotensin–aldosterone system;Weber;Circulation,1991

5. Mineralocorticoid receptor antagonists for heart failure with reduced ejection fraction: integrating evidence into clinical practice;Zannad;Eur. Heart J.,2012

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. B-type natriuretic peptide as diagnostic and prognostic marker in various forms of acute coronary syndrome;Pakistan Journal of Medical Sciences;2022-03-07

2. Effects of enalapril folic acid combined with levamlodipine on incidence of cardiovascular and cerebrovascular events in patients with essential hypertension;Materials Express;2021-10-01

3. Elimination of endogenous high molecular weight FGF2 prevents pressure-overload-induced systolic dysfunction, linked to increased FGFR1 activity and NR1D1 expression;Cell and Tissue Research;2021-05-31

4. Sacubitril/valsartan for heart failure with reduced ejection fraction: a first real-life observational study in Poland Sacubitril/valsartan for heart failure with reduced ejection fraction: A first real-life observational study in Poland;Advances in Clinical and Experimental Medicine;2021-02-02

5. Neprilysin Inhibitors: Filling a Gap in Heart Failure Management, Albeit Amidst Controversy and at a Significant Cost;American Journal of Cardiovascular Drugs;2018-06-20